Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Polyclonal Antibody Market, by Type (Primary Antibody and Secondary Antibody), By Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 987.7 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/4347
Rising incidence of cancer is expected to augment the market growth.
Rising incidence of cancer is expected to drive the polyclonal antibody market growth. For instance, according to an article published by the American Cancer Society, 2016, an estimated 16.8 million new cases of cancer are diagnosed every year in the U.S., with around 595,690 deaths occurring due to cancer. The number of people with cancer is expected to rise to 19 million by 2024.
Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus disease (COVID-19) has resulted in over 70.46 million infected individuals worldwide, as of December 13, 2020.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4347
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of raw materials from one place to another.
Key players in the market are focusing on inorganic strategies for development of polyclonal antibodies. For instance, in January 2018, Abcam plc, a manufacturer of life science research tools, signed an agreement with Roche Diagnostics, a healthcare subsidiary of F. Hoffmann-La Roche AG for the rights to the product portfolio of Spring Bioscience Corporation (Spring), acquired by Roche (2007). This product portfolio comprises of 500 additional products, predominantly other monoclonal and polyclonal antibodies.
Browse 40 Market Data Tables and 35 Figures spread through 202 Pages and in-depth TOC on “Polyclonal Antibody Market – by Type (Primary Antibody and Secondary Antibody), By Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027”
To know the latest trends and insights prevalent in the global polyclonal antibody market press release, click the link below: https://www.coherentmarketinsights.com/press-release/polyclonal-antibody-market-3607
Key Takeaways of the Global Polyclonal Antibody Market:
- The global polyclonal antibody market is expected to exhibit a CAGR of 5.2% during the forecast period owing to rising incidence of cancer globally. According to an article published by the Cancer Research UK in 2014, around 357,000 new cancer cases were diagnosed in the U.K., accounting for 980 diagnosed cases per day. Breast, prostate, lung, and bowel cancers together accounted for over 53% of the total cancers in the U.K.
- Among type, the secondary antibody segment held a dominant position in the global polyclonal antibody market in 2019 owing to better recognition of multiple epitopes on a primary antibody and are more sensitive towards antigens.
- Among application, the commercial segment held a dominant position in the polyclonal antibody market in 2019, owing to the rising demand for polyclonal antibodies in therapeutics by pharmaceutical and biotechnological companies.
- Key players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.
Detailed Segmentation:
- Global Polyclonal Antibody Market, By Type:
- Primary Antibody
- Secondary Antibody
- Global Polyclonal Antibody Market, By Application:
- Academic Research
- Commercial
- Global Polyclonal Antibody Market, By Region:
- North America
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- U.S.
- Canada
- By Type:
- Latin America
- By Type:
- By Application:
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type
- By Application:
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type:
- By Application:
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type:
- By Application:
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type:
- By Application:
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837